Read by QxMD icon Read

PD Adequacy

Ferga C Gleeson, Michael J Levy, Anja C Roden, Lisa A Boardman, Frank A Sinicrope, Robert R McWilliams, Lizhi Zhang
Background and study aims  The US FDA recently approved a cancer treatment with pembrolizumab based upon the tumor biomarker status of deficient mismatch repair (dMMR) rather than a specific disease-based approach. We sought to determine if endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) could determine dMMR and quantification of PD-L1 expression to potentially guide the delivery of tumor agnostic immunotherapy. Patients and methods  Immunohistochemistry was performed on archived pancreas core biopsy specimens...
October 2018: Endoscopy International Open
Tao Zhang, Yitian Dou, Xuejun Wang, Jing Li, Shili Cao
BACKGROUND/AIMS: Mounting clinical experience and evidence from scale observational studies have suggested that polycystic kidney disease (PKD) was not a contraindication for peritoneal dialysis (PD). Recent studies have reported that PD may be associated with a better prognosis in PKD than that of non-PKD patients. To solve the problem, we performed a systematic review and comprehensive meta-analysis to compare the outcomes between PKD and non-PKD patients on PD and the all-cause mortality between patients with PKD on PD and hemodialysis (HD)...
October 4, 2018: Kidney & Blood Pressure Research
Lana M Chahine, Thomas G Beach, Nicholas Seedorff, Chelsea Caspell-Garcia, Christopher S Coffey, Michael Brumm, Charles H Adler, Geidy E Serrano, Carly Linder, Sherri Mosovsky, Tatiana Foroud, Holly Riss, Dixie Ecklund, John Seibyl, Danna Jennings, Vanessa Arnedo, Lindsey Riley, Kuldip Dave, Brit Mollenhauer
BACKGROUND: α-synuclein is a lead Parkinson's disease (PD) biomarker. There are conflicting reports regarding accuracy of α-synuclein in different tissues and biofluids as a PD biomarker, and the within-subject anatomical distribution of α-synuclein is not well described. The Systemic Synuclein Sampling Study (S4) aims to address these gaps in knowledge. The S4 is a multicenter, cross-sectional, observational study evaluating α-synuclein in multiple tissues and biofluids in PD and healthy controls (HC)...
September 21, 2018: Journal of Parkinson's Disease
Constantinos Kormas, Ioannis Zalonis, Ioannis Evdokimidis, Constantin Potagas
In this study, we examined the performance of patients with Parkinson's disease (PD) with different cognitive profiles on the Face-Name Associative Memory Examination (FNAME). We evaluated 71 patients with a comprehensive neuropsychological battery. The results revealed that the group with executive and additional visuospatial deficits demonstrated significantly lower scores on FNAME. This finding indicates the possible clinical utility of FNAME for screening patients with PD with distinct cognitive profiles...
September 12, 2018: Neurological Sciences
Gilbert Bigras, Simon Mairs, Paul E Swanson, Didier Morel, Raymond Lai, Iyare Izevbaye
Pembrolizumab is an FDA-approved immune-checkpoint (IC) inhibitor that targets programmed cell death protein PD-1, and recent phase III trials have demonstrated its superiority over chemotherapy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Eligibility for treatment with Pembrolizumab is based on demonstration of PD-L1 expression on tumoral cells using the approved companion test 22C3 PharmDx (Dako). Access to the drug depends on a tumor proportion score (TPS) expressing the PD-L1 protein above predetermined cutoffs...
August 8, 2018: Applied Immunohistochemistry & Molecular Morphology: AIMM
Gonzalo Labarca, Erik Folch, Michael Jantz, Hiren J Mehta, Adnan Majid, Sebastian Fernandez-Bussy
BACKGROUND: Endobronchial ultrasound and transbronchial needle aspiration (EBUS-TBNA) are commonly used for the diagnosis and mediastinal staging of lung cancer. Molecular markers are becoming increasingly important in patients with lung cancer to define targetable mutations suitable for personalized therapy, such as EGFR, ALK, ROS-1, and PD-L1. OBJECTIVE: To evaluate the adequacy of EBUS-TBNA derived tissue for molecular analysis. DATA SOURCES: We searched MEDLINE, Lilacs, clinicaltrials...
July 16, 2018: Annals of the American Thoracic Society
Lucas de Francisco Carvalho, Catarina Possenti Sette, Fabiano Koich Miguel
OBJECTIVE: To investigate the clinical functioning of the criticism avoidance dimension from the Dimensional Clinical Personality Inventory 2 (Inventário Dimensional Clínico da Personalidade 2 [IDCP-2]), establishing a clinically relevant cut-off for the typical traits of avoidant personality disorder (AvPD) for screening purposes. METHODS: We administered the IDCP-2 to a sample of 2,276 subjects aged 18 to 90 years (mean = 26.95, standard deviation = 9.71). Of the total sample, 1,650 were women (67%) and most were college students (72...
2018: Trends in Psychiatry and Psychotherapy
Silvio Borrelli, Vincenzo La Milia, Luca De Nicola, Gianfranca Cabiddu, Roberto Russo, Michele Provenzano, Roberto Minutolo, Giuseppe Conte, Carlo Garofalo
Achievement of sodium and fluid balance is considered a major determinant of dialysis adequacy in peritoneal dialysis (PD). However, the contribution of different PD modalities to dialytic sodium removal (DSR) remains ill-defined. We performed a systematic review and meta-analysis to compare DSR by manual (continuous ambulatory PD, CAPD) versus automated PD (APD). Alternative PD strategies to remove sodium were also analyzed. Seven cohort studies, including 683 patients, 406 in CAPD and 277 in APD, were meta-analyzed out of the 30 studies selected based on DSR data availability...
July 5, 2018: Journal of Nephrology
Bianca Davidson, Kenneth Crombie, Kathryn Manning, Brian Rayner, Nicola Wearne
BACKGROUND: South Africa (SA) currently performs the most peritoneal dialysis (PD) in Africa. Yet outcome data on PD programs on the continent are limited. With the escalating need for renal replacement, PD remains a life-saving modality especially as hemodialysis is limited in the public sector. This study aims to evaluate and report the outcomes of a PD-First program performed in a resource-limited setting and identify factors linked to poor outcomes. METHODS: This observational cohort study was performed at Groote Schuur Hospital, analyzing all PD patients retrospectively from January 2008 to June 2014 and thereafter prospectively until June 2015...
May 2018: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Leslie Wilson, Fatema A Turkistani, Wei Huang, Dang M Tran, Tracy Kuo Lin
INTRODUCTION: California's Workers' Compensation System (CAWCS) Department of Industrial Relations questioned the adequacy of the current Medi-Cal fee-schedule pricing and requested analysis of alternatives that maximize price availability and maintain budget neutrality. OBJECTIVES: To compare CAWCS pharmacy-dispensed (PD) drug prices under alternative fee schedules, and identify combinations of alternative benchmarks that have prices available for the largest percentage of PD drugs and that best reach budget neutrality...
2018: PloS One
Sabrina Milan Manani, Carlo Crepaldi, Anna Giuliani, Grazia Maria Virzì, Francesco Garzotto, Caterina Riello, Massimo de Cal, Mitchell H Rosner, Claudio Ronco
BACKGROUND: Remote monitoring (RM) supports a healthcare model that enhances patients' self-management. We evaluated the utility of RM in patients undergoing automated peritoneal dialysis (APD). METHODS: We observed 37 -RM-APD patients, 16 incidents, and 21 prevalents switched from traditional APD (T-APD). We observed the number of changes for APD prescription, the frequency of visits, and PD adequacy parameters during 1 year of RM utilization in APD. RESULTS: The APD prescriptions were modified more frequently in RM-APD vs...
2018: Blood Purification
H Wang, J Agulnik, G Kasymjanova, A Wang, P Jiménez, V Cohen, D Small, C Pepe, L Sakr, P O Fiset, M Auger, S Camilleri-Broet, M Alam El Din, G Chong, L van Kempen, A Spatz
Background: PD-L1 immunohistochemistry (IHC) testing is usually carried out on tissue blocks from core needle biopsy or surgical resections. In this study, we assessed the feasibility of using cytology cell blocks for PD-L1 IHC assay. Methods: A total of 1419 consecutive cases of non-small-cell lung cancer (NSCLC), including 371 cytology cell blocks, 809 small biopsies, and 239 surgical specimens, were included in the study. The cytology cell blocks were prepared with formalin only, methanol/alcohol only or both...
June 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Jacques Rottembourg, Guy Rostoker
The share of peritoneal dialysis (PD) in the spectrum of chronic dialysis has decreased in France over the last ten years. Despite various facilities offered by the health authorities, PD remains confidential in many private units and some public hospitals. The enthusiasm present at the beginning of this technology, forty years ago, is declining, despite a real improvement in new developments, a real increase in patient survival, today at least similar to that on hemodialysis. Then, the aim of this review is first to give a summary of the principles and practice of patient and staff education and to describe the role of the medical contribution in decision-making...
April 11, 2018: Néphrologie & Thérapeutique
Suree Yoowannakul, Lauren S Harris, Andrew Davenport
Peritoneal protein clearance (PPCl) depends upon vascular supply and size selective permeability. Some previous reports suggested PPCl can distinguish fast peritoneal membrane transport due to local or systemic inflammation. However, as studies have been discordant, we wished to determine factors associated with an increased PPCl. Consecutive patients starting peritoneal dialysis (PD) who were peritonitis-free were studied. Data included a baseline peritoneal equilibration test (PET), measurement of dialysis adequacy, 24-h dialysate PPCl and body composition measured by multifrequency bioimpedance...
April 2018: Therapeutic Apheresis and Dialysis
Emily B Tsai, Kelsey Pomykala, Kathleen Ruchalski, Scott Genshaft, Fereidoun Abtin, Antonio Gutierrez, Hyun J Kim, Alice Li, Carlos Adame, Ashkan Jalalian, Brian Wolf, Edward B Garon, Jonathan W Goldman, Robert Suh
Purpose To determine feasibility and safety of biopsy and repeat biopsy for assessment of programmed cell death ligand-1 (PD-L1) status. Materials and Methods This retrospective analysis reviewed 101 patients who underwent transthoracic core needle biopsy for the KEYNOTE-001 (MK-3475) clinical trial of pembrolizumab, an antiprogrammed cell death-1 therapy for non-small cell lung cancer, from May 2012 to September 2014. Sixty-one male patients (mean age, 66.1 years; range 36-83 years) and 40 female patients (mean age, 66...
April 2018: Radiology
Christopher S B Sia, Eldho Paul, Peter Tregaskis, Rowan G Walker, Scott G Wilson
BACKGROUND: The longitudinal effects of peritoneal dialysis (PD) peritonitis on small solute clearance and ultrafiltration are controversial. MATERIALS AND METHODS: We identified 27 patients with PD peritonitis over a 4-year period at a tertiary hospital. Adequacy tests at an "early" (1 - 3 months), "intermediate" (6 ± 2 months), and a "late" (12 ± 2 months) time period after the episode were compared with a pre-peritonitis baseline...
December 2017: Clinical Nephrology
Sean P Stoy, Lauren Rosen, Jeffrey Mueller, Septimiu Murgu
BACKGROUND: Programmed death-ligand 1 (PD-L1) expression testing is recommended by guidelines for patients with advanced non-small cell lung cancer (NSCLC). The primary objective of the current study was to determine the success rate of PD-L1 testing from cytology cell block samples obtained by bronchoscopic needle aspiration. The secondary objective was the assessment of the difference in specimen adequacy acquired via needles of different gauges. METHODS: Patients with NSCLC who underwent bronchoscopic needle aspirations for which PD-L1 testing was requested between November 1, 2016, and February 6, 2017, were included in the current analysis...
February 2018: Cancer Cytopathology
Jonas J Heymann, William A Bulman, David Swinarski, Carlos A Pagan, John P Crapanzano, Mehrvash Haghighi, Ladan Fazlollahi, Mark B Stoopler, Joshua R Sonett, Adrian G Sacher, Catherine A Shu, Naiyer A Rizvi, Anjali Saqi
BACKGROUND: One immunotherapeutic agent for patients with advanced non-small cell lung carcinoma, pembrolizumab, has a companion immunohistochemistry (IHC)-based assay that predicts response by quantifying programmed death-ligand 1 (PD-L1) expression. The current study assessed the feasibility of quantifying PD-L1 expression using cytologic non-small cell lung carcinoma specimens and compared the results with those from small biopsy and surgical resection specimens. METHODS: PD-L1 expression was quantified using the IHC-based 22C3 pharmDx assay, with "positivity" defined as staining in ≥50% viable tumor cells; ≥ 100 tumor cells were required for test adequacy...
December 2017: Cancer Cytopathology
Sohail Abdul Salim, Yougandhar Akula, Swetha Kandhuri, Sabahat Afshan, Lajos Zsom, Mehul P Dixit, Tibor Fülöp
Peritoneal dialysis (PD) obviates the need for temporary vascular access in end-stage renal disease; however, extremely heavy weight has been viewed as a relative contraindication to PD.We performed a cross-sectional review of multiple clinical and laboratory variables for 75 current or past PD patients (vintage > 6 months), comparing dialysis adequacy parameters for those with a large body weight (>100 kg, LWS group) and with a normal body weight (<75 kg, NWS group).In the LWS group (n = 17), mean weight was 117...
2016: Advances in Peritoneal Dialysis
So Mi Kim, Eun Kyoung Lee, Shin Sook Kang, Soon Mi Kim, Hye-Won Kim, Soon Bae Kim
BACKGROUND AND OBJECTIVES: Restriction of dietary sodium intake for peritoneal dialysis (PD) patients is recommended, but there is limited information on the measurement and monitoring of sodium intake. We have developed a simple method to estimate daily sodium intake during the measurement of dialysis adequacy in PD patients. METHODS AND STUDY DESIGN: A total of 83 PD patients were enrolled in the study. The patients were divided into two groups based on residual renal function (RRF)...
2017: Asia Pacific Journal of Clinical Nutrition
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"